Stock listing
Celltrion, Inc.
Selected listing: 068270 · KRX · KRW · KR
Celltrion, Inc. (KRX:068270), Health Technology. Latest release Jul 27, 2026: Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW…
- Ticker
- KRX:068270
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
About Celltrion, Inc.
Celltrion, Inc. is a public company traded under the ticker 068270 on the Korean market. Celltrion is involved in the biopharmaceutical industry, focusing on the development and manufacturing of biosimilars and innovative drugs.
Latest news from Celltrion, Inc.
Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability
July 26, 2026
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
April 21, 2026
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
March 16, 2026
Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026